Literature DB >> 28383390

High Prevalence of Abacavir-associated L74V/I Mutations in Kenyan Children Failing Antiretroviral Therapy.

Eric J Dziuban1, Joshua DeVos, Bernadette Ngeno, Evelyn Ngugi, Guoqing Zhang, Jennifer Sabatier, Nick Wagar, Karidia Diallo, Lucy Nganga, Abraham Katana, Chunfu Yang, Emilia D Rivadeneira, Irene Mukui, Francesca Odhiambo, Robert Redfield, Elliot Raizes.   

Abstract

A survey of 461 HIV-infected Kenyan children receiving antiretroviral therapy found 143 (31%) failing virologically. Drug resistance mutations were found in 121; 37 had L74V/I mutations, with 95% receiving abacavir (ABC)-containing regimens. L74V/I was associated with current ABC usage (P = 0.0001). L74V/I may be more prevalent than previously realized in children failing ABC-containing regimens, even when time on treatment has been short. Ongoing rigorous pediatric drug resistance surveillance is needed.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28383390      PMCID： PMC6404536          DOI： 10.1097/INF.0000000000001597

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN： 0891-3668            Impact factor:   2.129


  5 in total

1.  Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool.

Authors:  Conan K Woods; Chanson J Brumme; Tommy F Liu; Celia K S Chui; Anna L Chu; Brian Wynhoven; Tom A Hall; Christina Trevino; Robert W Shafer; P Richard Harrigan
Journal:  J Clin Microbiol       Date:  2012-03-07       Impact factor: 5.948

2.  The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.

Authors:  Luis R Miranda; Matthias Götte; Fei Liang; Daniel R Kuritzkes
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

3.  Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children.

Authors:  Karl-Günter Technau; Erica Lazarus; Louise Kuhn; Elaine J Abrams; Gillian Sorour; Renate Strehlau; Gary Reubenson; Mary-Ann Davies; Ashraf Coovadia
Journal:  Pediatr Infect Dis J       Date:  2013-08       Impact factor: 2.129

4.  Long-term virologic response and genotypic resistance mutations in HIV-1 infected Kenyan children on combination antiretroviral therapy.

Authors:  Dalton C Wamalwa; Dara A Lehman; Sarah Benki-Nugent; Melanie A Gasper; Richard Gichohi; Elizabeth Maleche-Obimbo; Carey Farquhar; Grace C John-Stewart; Julie Overbaugh
Journal:  J Acquir Immune Defic Syndr       Date:  2013-03-01       Impact factor: 3.731

5.  High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen.

Authors:  Kim Steegen; Leon Levin; Irene Ketseoglou; Michelle Bronze; Maria A Papathanasopoulos; Sergio Carmona; Wendy Stevens
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240
  5 in total
  3 in total

1.  Utilization of dried blood spot specimens can expedite nationwide surveillance of HIV drug resistance in resource-limited settings.

Authors:  Guoqing Zhang; Joshua DeVos; Sandra Medina-Moreno; Nicholas Wagar; Karidia Diallo; R Suzanne Beard; Du-Ping Zheng; Christine Mwachari; Carolyn Riwa; Boniface Jullu; Ngugi Evelyn Wangari; Mary S Kibona; Lucy W Ng'Ang'A; Elliot Raizes; Chunfu Yang
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

2.  Genotyping performance evaluation of commercially available HIV-1 drug resistance test.

Authors:  Audu Rosemary; Onwuamah Chika; Okpokwu Jonathan; Imade Godwin; Odaibo Georgina; Okwuraiwe Azuka; Musa Zaidat; Chebu Philippe; Ezechi Oliver; Agbaji Oche; Olaleye David; Samuel Jay; Dalhatu Ibrahim; Ahmed Mukhtar; DeVos Joshua; Yang Chunfu; Raizes Elliot; Chaplin Beth; Kanki Phyllis; Idigbe Emmanuel
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

Review 3.  Antiviral Compounds from Myxobacteria.

Authors:  Lucky S Mulwa; Marc Stadler
Journal:  Microorganisms       Date:  2018-07-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.